Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Roche Holding Ltd. (ADR) (RHHBY), Bristol Myers Squibb Co. (BMY): Cancer Meeting Highlights the Good and Bad of the Immune System

Biotech investors rejoice. The ASCO abstracts are here. The annual meeting of the American Society of Clinical Oncology starts on May 31, but the organization releases most of the 4,700 abstracts — available here — tonight.

Here’s a breakdown of some of two themes we’ll see at the meeting.

Bristol Myers Squibb Co. (NYSE:BMY)

Harnessing the immune system
In theory, immune cells can recognize and kill tumors, but cancer cells have developed molecular breaks that tell the immune cells that they shouldn’t be killed. Drugs developed by Roche Holding Ltd. (ADR) (OTCBB:RHHBY) and Bristol Myers Squibb Co. (NYSE:BMY) are designed to block those breaks, allowing T cells to do their job.

The molecular break involves PD-L1 on the tumor cell binding to two receptors, PD-1 and B7.1, on the T cells, which signals to the T cell not to kill the tumor cell. There’s also another molecule in the same family called PD-L2 on tumors that also activates the blocking signal through PD-1.

Roche Holding Ltd. (ADR) (OTCBB:RHHBY)’s MPDL3280A acts on the tumor side, binding to PD-L1 to block the signal. Bristol Myers Squibb Co. (NYSE:BMY)’s nivolumab binds to PD-1 on the T cell to block the signal.

Both trials testing MPDL3280A and nivolumab are phase 1 trials, but they produced fairly remarkable results.

The trial that tested MPDL3280A in patients with lung, melanoma, kidney, head and neck, colorectal, and bladder cancers that had progressed after multiple prior treatment produced a 36% overall response rate in patients whose tumors stained positive for PD-L1. Of the 29 patients who responded to the drug — PD-L1 negative and positive — 26 continued to respond some three to 15 months later. That’s pretty impressive given the amount of pretreatment.

Nivolumab was combined with Yervoy, Bristol Myers Squibb Co. (NYSE:BMY)’s melanoma drug that stimulates the immune system in a different way. When the drugs were given concurrently, 53% of melanoma patients had an objective response with 41% seeing at least an 80% tumor deduction after just 12 weeks of treatment. Bristol Myers Squibb Co. (NYSE:BMY) plans to start a phase 3 trial of the combination in advanced melanoma this year.

What’s probably most amazing is how well this pathway seems to be conserved in different types of tumors. Roche Holding Ltd. (ADR) (OTCBB:RHHBY) tested six different cancer types, and Bristol Myers Squibb Co. (NYSE:BMY)’s combination therapy is also being tested in lung and renal cancers.

When the immune system is the problem
While the immune system can help eradicate tumors, it can sometimes go haywire itself, leading to leukemia.

Gilead Sciences, Inc. (NASDAQ:GILD)‘ idelalisib targets delta PI3K inhibitor, which moves signals from cell receptors to activate multiple pathways in B cells that promote cell growth and survival, among other things.